Mitochondria Death/Survival Signaling Pathways in Cardiotoxicity Induced by Anthracyclines and Anticancer-Targeted Therapies

Mitochondria Death/Survival Signaling Pathways in Cardiotoxicity Induced by Anthracyclines and Anticancer-Targeted Therapies

Anthracyclines remain the cornerstone of treatment in many malignancies but these agents have a cumulative dose relationship with cardiotoxicity. Development of cardiomyopathy and congestive heart failure induced by anthracyclines are typically dose-dependent, irreversible, and cumulative. Although...

Full description

Bibliographic Details
Main Authors:	David Montaigne, Christopher Hurt, Remi Neviere
Format:	Article
Language:	English
Published:	Hindawi Limited 2012-01-01
Series:	Biochemistry Research International
Online Access:	http://dx.doi.org/10.1155/2012/951539

Similar Items

Anthracycline Cardiotoxicity
by: Umberto Campia, MD, MSc, et al.
Published: (2020-06-01)

Cardiotoxicity of Anthracyclines
by: Daniela Cardinale, et al.
Published: (2020-03-01)

Cardiotoxicity in anthracycline therapy: Prevention strategies
by: Margarida Cruz, et al.
Published: (2016-06-01)

Anthracycline-induced cardiotoxicity : the role of proteolytic pathways
by: Sishi, Balindiwe J. N. (Balindiwe Jennifer Nonkosazana)
Published: (2012)

Anthracycline-Induced Cardiotoxicity
by: Jennifer E. Liu, MD
Published: (2020-03-01)

Anthracycline-Induced Cardiotoxicity
by: Radomír Hrdina, et al.
Published: (2000-01-01)

Dexrazoxane in anthracycline cardiotoxicity
by: Abhijit S Nair
Published: (2017-01-01)

The role of iron in anthracycline cardiotoxicity
by: Elena eGammella, et al.
Published: (2014-02-01)

Updates in Anthracycline-Mediated Cardiotoxicity
by: Canan G. Nebigil, et al.
Published: (2018-11-01)

Review on the pathophysiology of anthracycline-induced cardiotoxicity
by: Tiago Alexandre de Oliveira Valente
Published: (2019)

Risk Factors for Anthracycline-Induced Cardiotoxicity
by: Shuo Qiu, et al.
Published: (2021-09-01)

In vitro evaluation of anthracycline-induced cardiotoxicity and mitigation by perturbation of angiotensin signalling
by: Rockley, Kimberly Louise
Published: (2018)

The genetics of anthracycline-induced cardiotoxicity in cancer patients
by: Naidoo, Horacia
Published: (2018)

POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
by: V. I. Chernov, et al.
Published: (2016-02-01)

Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity
by: Marwa Tantawy, et al.
Published: (2021-01-01)

Detection of anthracycline induced cardiotoxicity by cardiac biomarkers
Published: (2020-11-01)

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
by: Ariane V.S. Macedo, MD, MSc, et al.
Published: (2019-09-01)

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
by: Neha Bansal, et al.
Published: (2019-12-01)

Cardiovascular magnetic resonance imaging in early anthracycline cardiotoxicity
by: Hugh Montgomery, et al.
Published: (2009-01-01)

Detection of Subclinical Anthracyclines' Cardiotoxicity in Children with Solid Tumor
by: Hui-Min Hu, et al.
Published: (2018-01-01)

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?
by: Alessandra Murabito, et al.
Published: (2020-03-01)

Assessing cardiotoxicity in randomised trials of anthracycline in cancer patients
by: Kerr, Amanda J.
Published: (2015)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01)

Targeting apoptosis signaling pathways for anticancer therapy
by: Simone eFulda
Published: (2011-08-01)

Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity
by: I. T. Murkamilov, et al.
Published: (2021-03-01)

Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity
by: Raquel Araujo-Gutierrez, et al.
Published: (2021-01-01)

Factors associated with anthracycline-induced cardiotoxicity in breast cancer patients
by: Elys María Pedraza-Rodríguez, et al.
Published: (2020-01-01)

Detection of subclinical anthracycline induced cardiotoxicity in breast cancer survivors
by: Preety Negi, et al.
Published: (2014-01-01)

The cardioprotective effects of probucol against Anthracycline and Trastuzumab mediated cardiotoxicity
by: Walker, Jonathan Robert
Published: (2010)

The cardioprotective effects of probucol against Anthracycline and Trastuzumab mediated cardiotoxicity
by: Walker, Jonathan Robert
Published: (2010)

Modeling anthracycline-induced cardiotoxicity with patient-specific iPSCs
by: Haupt, Luis Peter
Published: (2018)

Factors associated with anthracycline-induced cardiotoxicity in breast cancer patients
by: Elys María Pedraza-Rodríguez, et al.
Published: (2020-01-01)

The prospects for applications of cardiometric approach in evaluation of cardiotoxicity under Anthracyclines therapy in patients with breast cancer
by: Alla I. Shikhlyarova, et al.
Published: (2018-11-01)

Targeting mitochondria as an anticancer strategy
by: Lanfeng Dong, et al.
Published: (2019-10-01)

Cardiotoxicity of Anticancer Therapeutics
by: Jerry Dong, et al.
Published: (2018-02-01)

Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments
by: Anais Audebrand, et al.
Published: (2020-01-01)

Protects Against Anthracycline-Induced Cardiotoxicity in Early Breast Cancer Patients
by: Wei Hao MD, et al.
Published: (2020-07-01)

Exercise Attenuates Cardiotoxicity of Anthracycline Chemotherapy Measured by Global Longitudinal Strain
by: Benedict T. Costello, MBBS, PhD, et al.
Published: (2019-12-01)

Assessment of anthracycline-induced long-term cardiotoxicity in patients with hematological malignancies
by: Ala Ali
Published: (2020-01-01)

Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity
by: Becky Meiners, et al.
Published: (2018-08-01)